Quick PT-141 dosage facts (evidence-based)
- Active ingredient: bremelanotide.
- Approved reference: Vyleesi (US). Indication: acquired, generalised HSDD in premenopausal women.
- Label dose: 1.75 mg subcutaneous, on demand ~45 minutes before anticipated activity.
- Frequency limits: not more than once within 24 hours; maximum 8 doses per month.
- Common reactions: nausea, flushing, headache; transient increases in blood pressure and reductions in heart rate have been reported.
- Key cautions: avoid if you have uncontrolled hypertension or significant cardiovascular disease; discuss pregnancy, breastfeeding, and comorbidities with a doctor.
Forms and strengths: how PT-141 is supplied
Understanding product form is critical to dosing. The US-approved form is a single-use, prefilled autoinjector delivering 1.75 mg subcutaneously. Outside that, people may encounter compounded vials or unapproved nasal sprays online. These vary in concentration, quality and bioavailability.
- Autoinjector (labelled 1.75 mg): fixed-dose, on-demand use, consistent delivery.
- Compounded vials (e.g., 10 mg): require reconstitution; dose typically measured in mg based on clinician direction. Potency and sterility depend on the source.
- Nasal sprays: not an approved dosage form; absorption can be inconsistent and strengths differ. Medical oversight is important if considered.
Dosing always depends on the actual strength and form you have, plus your health profile and tolerability.
Injection and reconstitution basics · Get help matching dose to form
Online protocols vs the product label
Many “protocols” circulate online for PT-141. It helps to separate label-backed directions from anecdotal approaches:
- Label-backed (Vyleesi): single 1.75 mg subcutaneous dose as needed; max once per 24 hours; max 8 per month.
- Common anecdotal claims: “test” or “titrate” doses at 0.25–0.5 mg; typical ranges 0.5–1.75 mg; occasional “loading phases” (e.g., frequent micro-doses over 1–2 weeks). These are off-label and may raise side-effect risk without proven added benefit.
- Nasal spray claims: often described in “sprays per dose” or “mcg per spray,” but real absorption is variable. Without validated pharmacokinetics, outcomes can be unpredictable.
If you and your clinician consider off-label dosing, they may individualise a lower starting dose to assess nausea and flushing, then adjust as tolerated.
Timing, onset and frequency
- When to dose: about 45 minutes before anticipated activity (per label). Some users report onset from ~30 minutes up to a few hours.
- How often: no more than one dose within 24 hours; no more than 8 doses in a 30‑day period (label guidance reflects blood pressure and tolerability concerns).
- Food and nausea: some clinicians suggest dosing when you’re not overly full and staying well hydrated to help with tolerability; follow your clinician’s advice.
Titration and practical tips (clinician-directed)
Responses vary. Under medical supervision, some people start below 1.75 mg to evaluate nausea, flushing and blood-pressure effects, then adjust. Practical considerations discussed in clinic settings may include:
- Start low if prone to nausea; remain supine if you feel light-headed.
- Avoid alcohol or other agents that may worsen flushing or blood pressure changes.
- Rotate injection sites (abdomen or thigh) to minimise irritation when using reconstituted vials.
- Keep within monthly and 24‑hour limits.
These points are general information only; follow your prescriber’s instructions.
Safety, side effects and who should avoid PT-141
Common reactions include nausea (sometimes significant), flushing, headache, and injection-site reactions. Transient increases in blood pressure and decreases in heart rate have been reported after dosing.
- Not suitable for everyone: avoid use with uncontrolled hypertension or significant cardiovascular disease; discuss migraine history, pregnancy, breastfeeding and kidney/liver issues with a doctor.
- Pigmentation: some people report darkening of gums or skin, particularly with other melanocortin agents.
- Drug combinations: combining with other agents that affect blood pressure or nausea should be clinician‑supervised.
Injection and reconstitution basics
If you receive reconstituted PT-141 from a medical provider, your dosing instructions should specify the concentration, exact volume to draw, and injection technique. For general technique and hygiene principles:
Australian access and legal context
In Australia, bremelanotide (PT-141) is not widely approved for routine supply. Access, if considered, generally occurs via a registered prescriber through pathways such as the TGA’s Special Access Scheme or Authorised Prescriber programs. Buying “research peptides” or importing without proper authority can breach Australian law and risks counterfeit or unsafe products.
Learn more: Is PT-141 legal in Australia? · PT-141 prescription: when it’s required · Safer access and red flags · Are peptides legal in Australia?
Frequently asked questions
What is the typical PT-141 dose?
The label-backed dose for Vyleesi is 1.75 mg subcutaneously on demand about 45 minutes before activity, not more than once in 24 hours and no more than 8 times per month.
Do men and women use the same PT-141 dose?
Evidence is strongest in premenopausal women with HSDD. Use in men is off-label with less formal data; dosing should be clinician-directed.
Can I microdose PT-141?
Microdosing appears in forums but is off-label and not supported by the product label. Discuss risks and benefits with a prescriber.
Is the nasal spray form reliable?
It is not an approved dosage form and absorption can be variable. Medical guidance is important if considered.
What if I get severe nausea?
Stop and seek medical advice. Some clinicians adjust dose or timing, or consider anti‑nausea strategies; this requires professional oversight.
Can PT-141 be combined with sildenafil or tadalafil?
Only under medical guidance. Both PT-141 and ED medicines can affect cardiovascular parameters.
Free help: ask us a PT-141 question
We provide general information to help you understand PT-141 dosage, safety and Australian access pathways. We do not replace medical advice. If you need personalised dosing or prescriptions, we can point you toward legitimate clinical routes.
Prefer a quick chat? Contact us
Key takeaways
- Label-backed dosing is 1.75 mg SC on demand, with strict 24‑hour and monthly limits.
- Online protocols vary and are off-label; clinician oversight is essential if considered.
- Forms differ (autoinjector vs compounded vs nasal); dose depends on strength and bioavailability.
- Side effects and blood-pressure changes mean suitability and dosing should be medically assessed.